These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23648367)

  • 1. Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial.
    Etoom Y; Banihani R; Finkelstein Y
    J Popul Ther Clin Pharmacol; 2013; 20(2):e91-4. PubMed ID: 23648367
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
    Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Kawasaki disease: corticosteroids revisited.
    Son MB; Newburger JW
    Lancet; 2012 Apr; 379(9826):1571-2. PubMed ID: 22405252
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
    Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prednisolone therapy for Kawasaki disease].
    Kobayashi T; Kobayashi T; Arakawa H
    Nihon Rinsho; 2014 Sep; 72(9):1623-8. PubMed ID: 25518413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kawasaki disease: an essential comparison of coronary artery aneurysm criteria.
    Burns JC; Hoshino S; Kobayashi T
    Lancet Child Adolesc Health; 2018 Dec; 2(12):840-841. PubMed ID: 30337184
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
    Dale RC; Saleem MA; Daw S; Dillon MJ
    J Pediatr; 2000 Nov; 137(5):723-6. PubMed ID: 11060542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
    Brogan P; Levin M
    Evid Based Med; 2013 Dec; 18(6):217-8. PubMed ID: 23564929
    [No Abstract]   [Full Text] [Related]  

  • 10. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
    Goto M; Miyagawa N; Kikunaga K; Miura M; Hasegawa Y
    Endocr J; 2015; 62(2):145-51. PubMed ID: 25342092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH; Chen MR; Hwang FY; Kao HA; Hung HY; Hsu CH
    Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants.
    Catalano-Pons C; Quartier P; Leruez-Ville M; Kaguelidou F; Gendrel D; Lenoir G; Casanova JL; Bonnet D
    Clin Infect Dis; 2005 Sep; 41(5):e53-6. PubMed ID: 16080076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
    Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S; Dong Y; Yin Y; Krucoff MW
    Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M; Shulman ST
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome.
    Rigante D; Andreozzi L; Fastiggi M; Bracci B; Natale MF; Esposito S
    Int J Mol Sci; 2016 Feb; 17(3):278. PubMed ID: 26927060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
    Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
    JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Kawasaki disease: what you need to know].
    Bajolle F; Laux D
    Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.